DelveInsight’s ‘Type 1 Diabetes Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline type 1 diabetes therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the type 1 diabetes pipeline domain.
Key Takeaways from the Type 1 Diabetes Pipeline Report
Request a sample and discover the recent advances in type 1 diabetes treatment drugs @ Type 1 Diabetes Clinical trial Outlook
The type 1 diabetes pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage type 1 diabetes products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the type 1 diabetes pipeline landscape.
Type 1 Diabetes Overview
Type 1 diabetes mellitus (T1DM) is an autoimmune disease that causes the loss of insulin-producing pancreatic beta cells. Insulin is a necessary anabolic hormone that influences glucose, lipid, protein, and mineral metabolism, as well as growth. The exact type 1 diabetes causes are unknown. T1DM develops in three phases. Stage 1 is asymptomatic and is distinguished by normal fasting glucose, normal glucose tolerance, and the presence of more than or equivalent to two pancreatic autoantibodies.
Type 1 diabetes symptoms might occur unexpectedly and include frequent urine, weight loss, blurry vision, tiredness, weakness, and others. The blood test is the most common method for type 1 diabetes diagnosis.
Find out more about type 1 diabetes treatment drugs @ Type 1 Diabetes Medications
A snapshot of the Type 1 Diabetes Pipeline Drugs mentioned in the report:
Drugs
Company
Teplizumab
Prevention Bio
Dasiglucagon
Zealand Pharma
AT-1501
Eledon Pharmaceuticals
AVT001
Avotres
IMCY-0098
ImCyse
Iscalimab
Novartis
Emricasan
Histogen
VX-880
Vertex Pharmaceuticals
NNC0363 0845
Novo Nordisk
Eflornithine
Panbela Therapeutics
LABP 111
Landos Biopharma
Learn more about the novel and emerging type 1 diabetes pipeline therapies @ Type 1 Diabetes Clinical Trials
Type 1 Diabetes Therapeutics Assessment
The type 1 diabetes pipeline report proffers an integral view of the type 1 diabetes emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Type 1 Diabetes Pipeline Report
Dive deep into rich insights for new drugs for type 1 diabetes treatment, visit @ FDA-approved Type 1 Diabetes Drugs
Table of Contents
1.
Type 1 Diabetes Pipeline Report Introduction
2.
Type 1 Diabetes Pipeline Report Executive Summary
3.
Type 1 Diabetes Pipeline: Overview
4.
Analytical Perspective In-depth Commercial Assessment
5.
Type 1 Diabetes Pipeline Therapeutics
6.
Type 1 Diabetes Pipeline: Late Stage Products (Pre-registration)
7.
Teplizumab: Prevention Bio
8.
Type 1 Diabetes Pipeline: Late Stage Products (Phase III)
9.
Dasiglucagon: Zealand Pharma
10.
Type 1 Diabetes Pipeline: Mid Stage Products (Phase II)
11.
IMCY-0098: ImCyse
12
Type 1 Diabetes Pipeline: Early Stage Products (Phase I)
13.
NNC0363 0845: Novo Nordisk
14.
Type 1 Diabetes Pipeline Therapeutics Assessment
15.
Inactive Products in the Type 1 Diabetes Pipeline
16.
Company-University Collaborations (Licensing/Partnering) Analysis
17.
Key Companies
18.
Key Products in the Type 1 Diabetes Pipeline
19.
Unmet Needs
20.
Market Drivers and Barriers
21.
Future Perspectives and Conclusion
22.
Analyst Views
23.
Appendix
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/type-1-diabetes-pipeline-insight